Published in J Addict Med on June 01, 2010
The adoption of alcohol pharmacotherapies in the Clinical Trials Network: the influence of research network participation. J Subst Abuse Treat (2010) 1.30
Implementing drug abuse treatment services in criminal justice settings: Introduction to the CJ-DATS study protocol series. Health Justice (2013) 1.19
Perceptions of the state policy environment and adoption of medications in the treatment of substance use disorders. Psychiatr Serv (2012) 1.09
Physicians in the substance abuse treatment workforce: understanding their employment within publicly funded treatment organizations. J Subst Abuse Treat (2012) 0.98
Adoption of evidence-based clinical innovations: the case of buprenorphine use by opioid treatment programs. Med Care Res Rev (2013) 0.97
Disparities in access to physicians and medications for the treatment of substance use disorders between publicly and privately funded treatment programs in the United States. J Stud Alcohol Drugs (2013) 0.96
Financial factors and the implementation of medications for treating opioid use disorders. J Addict Med (2012) 0.95
Patient characteristics and availability of onsite non-rapid and rapid HIV testing in US substance use disorder treatment programs. J Subst Abuse Treat (2012) 0.91
Nurse turnover in substance abuse treatment programs affiliated with the National Drug Abuse Treatment Clinical Trials Network. J Subst Abuse Treat (2010) 0.86
The transition to medication adoption in publicly funded substance use disorder treatment programs: organizational structure, culture, and resources. J Stud Alcohol Drugs (2014) 0.83
Dissemination, adoption, and implementation of acamprosate for treating alcohol use disorders. J Stud Alcohol Drugs (2014) 0.82
Innovation attributes and adoption decisions: perspectives from leaders of a national sample of addiction treatment organizations. J Subst Abuse Treat (2014) 0.82
Rural substance use treatment centers in the United States: an assessment of treatment quality by location. Am J Drug Alcohol Abuse (2015) 0.77
Counselor training and attitudes toward pharmacotherapies for opioid use disorder. Subst Abus (2015) 0.77
Examining the sustainment of the Adolescent-Community Reinforcement Approach in community addiction treatment settings: protocol for a longitudinal mixed method study. Implement Sci (2014) 0.77
Access to Addiction Pharmacotherapy in Private Health Plans. J Subst Abuse Treat (2016) 0.75
The employment of nurses in publicly funded substance abuse treatment programs. J Addict Nurs (2012) 0.75
The Diffusion of Acamprosate for the Treatment of Alcohol Use Disorder: Results From a National Longitudinal Study. J Subst Abuse Treat (2015) 0.75
Medscape's response to the Institute of Medicine Report: Crossing the quality chasm: a new health system for the 21st century. MedGenMed (2001) 38.72
Shattuck lecture--clinical research to clinical practice--lost in translation? N Engl J Med (2003) 9.40
A conceptual framework for transferring research to practice. J Subst Abuse Treat (2002) 6.76
Can the national addiction treatment infrastructure support the public's demand for quality care? J Subst Abuse Treat (2003) 5.97
Disseminating evidence-based practices in substance abuse treatment: a review with suggestions. J Subst Abuse Treat (2006) 5.02
Economic and demographic trends signal an impending physician shortage. Health Aff (Millwood) (2002) 4.77
Adoption and implementation of new technologies in substance abuse treatment. J Subst Abuse Treat (2002) 3.91
Direct care workers in the National Drug Abuse Treatment Clinical Trials Network: characteristics, opinions, and beliefs. Psychiatr Serv (2007) 3.38
Research to practice: adoption of naltrexone in alcoholism treatment. J Subst Abuse Treat (2003) 2.91
Innovation adoption in substance abuse treatment: exposure, trialability, and the Clinical Trials Network. J Subst Abuse Treat (2007) 2.88
A survey of clinical practices and readiness to adopt evidence-based practices: Dissemination research in an addiction treatment system. J Subst Abuse Treat (2004) 2.87
Bridging the gap: a hybrid model to link efficacy and effectiveness research in substance abuse treatment. Psychiatr Serv (2003) 2.77
Early adoption of buprenorphine in substance abuse treatment centers: data from the private and public sectors. J Subst Abuse Treat (2006) 2.73
Modeling the use of innovations in private treatment organizations: the role of absorptive capacity. J Subst Abuse Treat (2004) 2.51
The adoption of medications in substance abuse treatment: associations with organizational characteristics and technology clusters. Drug Alcohol Depend (2006) 2.30
Benefits of linking primary medical care and substance abuse services: patient, provider, and societal perspectives. Arch Intern Med (2001) 2.25
Trends in the adoption of medications for alcohol dependence. J Clin Psychopharmacol (2006) 2.13
Smoking cessation services in U.S. methadone maintenance facilities. Psychiatr Serv (2004) 2.08
Organizational correlates of access to primary care and mental health services in drug abuse treatment units. J Subst Abuse Treat (1999) 2.06
Strategies for disseminating evidence-based practices to staff who treat people with serious mental illness. Psychiatr Serv (2001) 2.03
Pharmacological treatment of alcohol dependence: a review of the evidence. JAMA (1999) 1.99
The federal role in drug abuse technology transfer: a history and perspective. J Subst Abuse Treat (2002) 1.91
Understanding US addiction physicians' low rate of naltrexone prescription. Drug Alcohol Depend (2003) 1.86
Adoption of naltrexone to treat alcohol dependence. J Subst Abuse Treat (2005) 1.84
Medications development: successes and challenges. Pharmacol Ther (2005) 1.80
Challenges in the adoption of new pharmacotherapeutics for addiction to alcohol and other drugs. Pharmacol Ther (2005) 1.64
Client and counselor attitudes toward the use of medications for treatment of opioid dependence. J Subst Abuse Treat (2006) 1.61
Effect of primary medical care on addiction and medical severity in substance abuse treatment programs. J Gen Intern Med (2003) 1.51
The gap between research and practice in substance abuse treatment. Psychiatr Serv (2002) 1.50
Physicians' opinions about medications to treat alcoholism. Addiction (2003) 1.43
Organizational-level predictors of adoption across time: naltrexone in private substance-use disorders treatment centers. J Stud Alcohol Drugs (2007) 1.39
The use of antidepressant medications in substance abuse treatment: the public-private distinction, organizational compatibility, and the environment. J Health Soc Behav (2007) 1.39
Role of state policies in the adoption of naltrexone for substance abuse treatment. Health Serv Res (2008) 1.39
Characteristics of U.S. substance abuse treatment facilities adopting buprenorphine in its initial stage of availability. Drug Alcohol Depend (2006) 1.38
Barriers to the use of medications to treat alcoholism. Am J Addict (2003) 1.36
Trends in comprehensive service availability in outpatient drug abuse treatment. J Subst Abuse Treat (2003) 1.34
A categorical typology of naltrexone-adopting private substance abuse treatment centers. J Subst Abuse Treat (2007) 1.34
State policies matter: the case of outpatient drug treatment program practices. J Subst Abuse Treat (2007) 1.33
What's next for translation research? Eval Health Prof (2006) 1.29
The economics of public health: financing drug abuse treatment services. Health Policy (2003) 1.19
Pharmacotherapy of alcoholism: gaps in knowledge and opportunities for research. Alcohol Alcohol (2001) 1.18
Dimensions of publicness and performance in substance abuse treatment organizations. J Policy Anal Manage (2004) 1.05
A discussion of the concept of technology transfer of research-based drug "abuse" prevention and treatment interventions. Subst Use Misuse (2002) 0.97
The future of the nurse shortage: will wage increases close the gap? Health Aff (Millwood) (2003) 0.97
Racial and ethnic disparities in SSRI availability in substance abuse treatment. Psychiatr Serv (2007) 0.96
Provision of on-site medical care to patients with hepatitis C in drug treatment units. J Health Care Poor Underserved (2004) 0.92
Adolescent and young adult heroin patients: drug use and success in methadone maintenance treatment. J Addict Dis (2006) 0.88
Innovation adoption in substance abuse treatment: exposure, trialability, and the Clinical Trials Network. J Subst Abuse Treat (2007) 2.88
Retaining counseling staff at substance abuse treatment centers: effects of management practices. J Subst Abuse Treat (2003) 2.84
Early adoption of buprenorphine in substance abuse treatment centers: data from the private and public sectors. J Subst Abuse Treat (2006) 2.73
Modeling the use of innovations in private treatment organizations: the role of absorptive capacity. J Subst Abuse Treat (2004) 2.51
Buprenorphine diffusion: the attitudes of substance abuse treatment counselors. J Subst Abuse Treat (2005) 2.36
The adoption of medications in substance abuse treatment: associations with organizational characteristics and technology clusters. Drug Alcohol Depend (2006) 2.30
Counselor emotional exhaustion and turnover intention in therapeutic communities. J Subst Abuse Treat (2006) 2.13
Trends in the adoption of medications for alcohol dependence. J Clin Psychopharmacol (2006) 2.13
Problem drinking patterns among African Americans: the impacts of reports of discrimination, perceptions of prejudice, and "risky" coping strategies. J Health Soc Behav (2003) 1.97
Service delivery in substance abuse treatment: reexamining "comprehensive" care. J Behav Health Serv Res (2007) 1.93
Research participation and turnover intention: An exploratory analysis of substance abuse counselors. J Subst Abuse Treat (2007) 1.92
Adoption and implementation of medications in addiction treatment programs. J Addict Med (2011) 1.89
Buprenorphine adoption in the National Drug Abuse Treatment Clinical Trials Network. J Subst Abuse Treat (2009) 1.66
Clinical supervision, emotional exhaustion, and turnover intention: a study of substance abuse treatment counselors in the Clinical Trials Network of the National Institute on Drug Abuse. J Subst Abuse Treat (2008) 1.59
Structural and cultural barriers to the adoption of smoking cessation services in addiction treatment organizations. J Addict Dis (2010) 1.55
Opioid treatment programs in the Clinical Trials Network: representativeness and buprenorphine adoption. J Subst Abuse Treat (2008) 1.40
Research network involvement and addiction treatment center staff: counselor attitudes toward buprenorphine. Am J Addict (2007) 1.40
Organizational-level predictors of adoption across time: naltrexone in private substance-use disorders treatment centers. J Stud Alcohol Drugs (2007) 1.39
The use of antidepressant medications in substance abuse treatment: the public-private distinction, organizational compatibility, and the environment. J Health Soc Behav (2007) 1.39
Individual and network factors associated with prevalent hepatitis C infection among rural Appalachian injection drug users. Am J Public Health (2012) 1.35
A categorical typology of naltrexone-adopting private substance abuse treatment centers. J Subst Abuse Treat (2007) 1.34
Counselor attitudes toward the use of motivational incentives in addiction treatment. Am J Addict (2010) 1.33
Differences in prevalence of prescription opiate misuse among rural and urban probationers. Am J Drug Alcohol Abuse (2007) 1.30
The adoption of alcohol pharmacotherapies in the Clinical Trials Network: the influence of research network participation. J Subst Abuse Treat (2010) 1.30
Counselor attitudes toward pharmacotherapies for alcohol dependence. J Stud Alcohol Drugs (2009) 1.30
Barriers to the implementation of medication-assisted treatment for substance use disorders: the importance of funding policies and medical infrastructure. Eval Program Plann (2011) 1.25
Early adoption of injectable naltrexone for alcohol-use disorders: findings in the private-treatment sector. J Stud Alcohol Drugs (2010) 1.22
Predicting closure of private substance abuse treatment facilities. J Behav Health Serv Res (2002) 1.21
Availability of integrated care for co-occurring substance abuse and psychiatric conditions. Community Ment Health J (2006) 1.20
Partner relationships and HIV risk behaviors among women offenders. J Psychoactive Drugs (2008) 1.16
Individual and network factors associated with non-fatal overdose among rural Appalachian drug users. Drug Alcohol Depend (2010) 1.15
A longitudinal examination of alcohol pharmacotherapy adoption in substance use disorder treatment programs: patterns of sustainability and discontinuation. J Stud Alcohol Drugs (2011) 1.14
Job stress and poor sleep quality: data from an American sample of full-time workers. Soc Sci Med (2007) 1.10
Diffusion of contingency management and attitudes regarding its effectiveness and acceptability. Subst Abus (2010) 1.03
Evidence-based treatment for opiate-dependent clients: availability, variation, and organizational correlates. Am J Drug Alcohol Abuse (2006) 1.01
OxyContin® as currency: OxyContin® use and increased social capital among rural Appalachian drug users. Soc Sci Med (2012) 1.00
Total quality management and performance in substance abuse treatment centers. Health Serv Res (2010) 1.00
Occupational turnover intentions among substance abuse counselors. J Subst Abuse Treat (2010) 1.00
Health, mental health, substance use, and service utilization among rural and urban incarcerated women. Womens Health Issues (2007) 0.99
Physicians in the substance abuse treatment workforce: understanding their employment within publicly funded treatment organizations. J Subst Abuse Treat (2012) 0.98
Risky relationships: targeting HIV prevention for women offenders. AIDS Educ Prev (2012) 0.98
Organizational factors associated with the use of contingency management in publicly funded substance abuse treatment centers. J Subst Abuse Treat (2010) 0.97
Does service diversification enhance organizational survival?: Evidence from the private substance abuse treatment system. J Behav Health Serv Res (2005) 0.96
Racial and ethnic disparities in SSRI availability in substance abuse treatment. Psychiatr Serv (2007) 0.96
Disparities in access to physicians and medications for the treatment of substance use disorders between publicly and privately funded treatment programs in the United States. J Stud Alcohol Drugs (2013) 0.96
Rural and urban similarities and differences in private substance abuse treatment centers. J Psychoactive Drugs (2004) 0.96
Why are recovering substance abuse counselors paid less? Subst Abus (2007) 0.95
Financial factors and the implementation of medications for treating opioid use disorders. J Addict Med (2012) 0.95
HIV/AIDS services in private substance abuse treatment programs. Drug Alcohol Depend (2010) 0.95
Timing of buprenorphine adoption by privately funded substance abuse treatment programs: the role of institutional and resource-based interorganizational linkages. J Subst Abuse Treat (2011) 0.94
Counselor training in several evidence-based psychosocial addiction treatments in private US substance abuse treatment centers. Drug Alcohol Depend (2011) 0.94
A changed America? The effects of September 11th on depressive symptoms and alcohol consumption. J Health Soc Behav (2005) 0.94
Management systems, patient quality improvement, resource availability, and substance abuse treatment quality. Health Serv Res (2011) 0.94
The availability of psychiatric programs in private substance abuse treatment centers, 1995 to 2001. Psychiatr Serv (2004) 0.93
Examination of an interventionist-led HIV intervention among criminal justice-involved female prisoners. J Exp Criminol (2009) 0.93
Injection risk behaviors among rural drug users: implications for HIV prevention. AIDS Care (2011) 0.92
Patient characteristics and availability of onsite non-rapid and rapid HIV testing in US substance use disorder treatment programs. J Subst Abuse Treat (2012) 0.91
The relationship of stress, impulsivity, and beliefs to drug use severity in a sample of women prison inmates. Int J Offender Ther Comp Criminol (2007) 0.89
Drug abuse treatment beyond prison walls. Addict Sci Clin Pract (2009) 0.89
What are the correlates of substance abuse treatment counselor salaries? J Subst Abuse Treat (2005) 0.88
Racial and Gender Discrimination in the Stress Process: Implications for African American Women's Health and Well-Being. Sociol Perspect (2013) 0.88
Predominantly female caseloads: identifying organizational correlates in private substance abuse treatment centers. J Behav Health Serv Res (2004) 0.88
Reducing risky relationships: a multisite randomized trial of a prison-based intervention for reducing HIV sexual risk behaviors among women with a history of drug use. AIDS Care (2014) 0.87
Modified therapeutic communities and adherence to traditional elements. J Psychoactive Drugs (2009) 0.86
Counselor attitudes toward the use of naltrexone in substance abuse treatment: a multi-level modeling approach. Addict Behav (2011) 0.86
Nurse turnover in substance abuse treatment programs affiliated with the National Drug Abuse Treatment Clinical Trials Network. J Subst Abuse Treat (2010) 0.86
Racial and Ethnic Composition as a Correlate of Medication Availability within Addiction Treatment Organizations. Sociol Focus (2009) 0.85
Turnover intention and emotional exhaustion "at the top": adapting the job demands-resources model to leaders of addiction treatment organizations. J Occup Health Psychol (2009) 0.85
Assessment and treatment of co-occurring eating disorders in publicly funded addiction treatment programs. Psychiatr Serv (2008) 0.85
Increasing prevalence of prescription opiate misuse over time among rural probationers. J Opioid Manag (2007) 0.84
The use of art and music therapy in substance abuse treatment programs. J Addict Nurs (2014) 0.83
Drug use and criminal activity among rural probationers with DUI histories. Int J Offender Ther Comp Criminol (2008) 0.83
The roles of spirituality in the relationship between traumatic life events, mental health, and drug use among African American women from one southern state. Subst Use Misuse (2013) 0.83
Prevalence of HIV and risky sexual behaviors among rural drug users: does age matter? Ann Epidemiol (2012) 0.83
Dissemination activities: a critical new role for substance abuse treatment organizations. J Behav Health Serv Res (2014) 0.82
Gender-specific factors associated with community substance abuse treatment utilization among incarcerated substance users. Int J Offender Ther Comp Criminol (2008) 0.82
Quality of clinical supervision and counselor emotional exhaustion: the potential mediating roles of organizational and occupational commitment. J Subst Abuse Treat (2013) 0.80
Hepatitis C viremia and genotype distribution among a sample of nonmedical prescription drug users exposed to HCV in rural Appalachia. J Med Virol (2012) 0.80
The relationship between Clinical Trial Network protocol involvement and quality of substance use disorder treatment. J Subst Abuse Treat (2013) 0.79
Kentucky rural stimulant use: a comparison of methamphetamine and other stimulant users. J Psychoactive Drugs (2007) 0.79
Controlled-release oxycodone admissions in public and private substance abuse treatment: associations with organizational characteristics. J Addict Dis (2007) 0.79
Counselor attitudes toward and use of evidence-based practices in private substance use disorder treatment centers: a comparison of social workers and non-social workers. Health Soc Work (2012) 0.79
Social workers' knowledge and perceptions of effectiveness and acceptability of medication assisted treatment of substance use disorders. Soc Work Health Care (2013) 0.79
Perception of Eligible Black Men as a Context for HIV Risk Behavior Among Black Women. J Community Psychol (2013) 0.78
Feeling good in your own skin: the influence of complimentary sexual stereotypes on risky sexual attitudes and behaviors in a community sample of African American women. Women Health (2013) 0.78
Drug use, hepatitis C, and service availability: perspectives of incarcerated rural women. Soc Work Public Health (2015) 0.77
Substance Use, Criminal Activity, and Mental Health Among Violent and Nonviolent Rural Probationers. J Addict Offender Couns (2010) 0.77
The availability of integrated care in a national sample of therapeutic communities. J Behav Health Serv Res (2012) 0.77
Too Much of a Good Thing? Psychosocial Resources, Gendered Racism, and Suicidal Ideation Among Low-SES African American Women. Soc Psychol Q (2012) 0.77
An exploratory study of alternative configurations of governing boards of substance abuse treatment centers. J Subst Abuse Treat (2011) 0.77
Rural substance use treatment centers in the United States: an assessment of treatment quality by location. Am J Drug Alcohol Abuse (2015) 0.77
The moderating effects of skin color and ethnic identity affirmation on suicide risk among low-SES African American women. Race Soc Probl (2012) 0.77
Assessment and treatment of co-occurring eating disorders in privately funded addiction treatment programs. Am J Addict (2011) 0.77
Substance abuse treatment for older adults in private centers. Subst Abus (2011) 0.76
Adopting evidence-based medically assisted treatments in substance abuse treatment organizations: roles of leadership socialization and funding streams. J Health Hum Serv Adm (2014) 0.76
Job frustration in substance abuse counselors working with offenders in prisons versus community settings. Int J Offender Ther Comp Criminol (2013) 0.75
Incentive-Related Human Resource Practices for Substance Use Disorder Counselors: Salaries, Benefits, and Training. Alcohol Treat Q (2011) 0.75